PB2225: A RANDOMIZED OPEN-LABEL, PHASE 3 STUDY OF IMETELSTAT VS BEST AVAILABLE THERAPY IN INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS RELAPSED/REFRACTORY TO JAK INHIBITOR (IMPACTMF)

• John Mascarenhas,
• Claire Harrison,
• Jean-Jacques Kiladjian,
• Katja Sockel,
• Alessandro Vannucchi,
• Tymara Berry,
• Denise Redding,
• Laurie Sherman,
• Souria Dougherty,
• Lixian Peng,
• Libo Sun,
• Fei Huang,
• Ying Wan,
• Vivian Rodolf,
• Judy Ho,
• Shyamala Navada,
• Rami S. Komrokji

Affiliations

John Mascarenhas

1 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, United States

Claire Harrison

2 Guy’s and St Thomas’ Hospital, London, United Kingdom

Jean-Jacques Kiladjian

3 Hôpital Saint-Louis, Université Paris, Paris, France

Katja Sockel

4 Medical Clinic I, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany

Alessandro Vannucchi

5 AOU Careggi, University of Florence, Florence, Italy

Tymara Berry

6 Geron Corporation, Parsippany, United States

Denise Redding

6 Geron Corporation, Parsippany, United States

Laurie Sherman

6 Geron Corporation, Parsippany, United States

Souria Dougherty

6 Geron Corporation, Parsippany, United States

Lixian Peng

6 Geron Corporation, Parsippany, United States

Libo Sun

6 Geron Corporation, Parsippany, United States

Fei Huang

6 Geron Corporation, Parsippany, United States

Ying Wan

6 Geron Corporation, Parsippany, United States

Vivian Rodolf

6 Geron Corporation, Parsippany, United States

Judy Ho

6 Geron Corporation, Parsippany, United States

Shyamala Navada

6 Geron Corporation, Parsippany, United States

Rami S. Komrokji

7 Moffitt Cancer Center, Tampa, United States